<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755818</url>
  </required_header>
  <id_info>
    <org_study_id>220939</org_study_id>
    <nct_id>NCT02755818</nct_id>
  </id_info>
  <brief_title>Study of the Relationship Between Body Composition, Insulin Resistance and HDL Levels</brief_title>
  <official_title>The Independent Effect of Level of Kidney Function and Body Composition On Establishing HDL Cholesterol Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dialysis Clinic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 20 million people in the United States have some form of kidney failure. People
      with kidney failure have an increased chance of having low levels of high density lipid
      (HDL), so called &quot;good cholesterol.&quot; Patients who are overweight or obese also have low
      levels of HDL. The investigators are trying to find out whether causes of low HDL are the
      same in people who are overweight and in patients with kidney failure so that in the future
      doctors can better treat low HDL cholesterol levels. People with low levels of HDL are more
      likely to have heart attacks and strokes and are more likely to lose kidney function. This
      study hope to learn more about how kidney failure causes low HDL cholesterol levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is not a treatment or outcome trial.This is a single center cross sectional
      analysis of body composition and lipoprotein level and structure among patients with graded
      levels of renal failure in comparison to control subjects. To study the relationship between
      HDL cholesterol and both body composition and insulin resistance measured as homeostatic
      model assessment (HOMA) among a cohort of non diabetic non-proteinuric patients with advanced
      chronic kidney disease (CKD) compared to non diabetic subjects having normal kidney function.
      Renal patients chosen will be with advanced CKD stage 3, Stage 4, and stage 5 - which is end
      stage renal failure (ESRD) and on hemodialysis. Fasting blood will be taken for the
      evaluation of baseline lipid and renal function, and blood glucose level to make sure that
      there is no recent evidence of diabetes. Body compositions will be measured with 2
      established methods: DEXA and whole body bio-impedance spectroscopy (BIS). Fat mass and
      analysis will be estimated so as to provide a relationship between adiposity, insulin
      resistance, residual renal function and HDL levels and structure.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient patients with CKD willing to be injected with heparin
  </why_stopped>
  <start_date type="Actual">October 22, 2008</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HDL (High Density Lipoprotein) Level in Control and Chronic Kidney Disease (CKD 3b, 4, 5) Groups</measure>
    <time_frame>HDL (high density lipoprotein) (mg/dL) -- this is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
    <description>HDL (high-density lipoprotein), is called &quot;good&quot; cholesterol. It binds to cholesterols marked for disposal back to the liver to be digested and disposed by the body. High HDL level may lower your risk for heart disease and stroke.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL Level in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</measure>
    <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
    <description>LDL (low-density lipoprotein), is a type of cholesterol (fat) circulating in the blood vessels, and can form plaques. High levels of LDL cholesterol may raise your risk for heart disease and stroke.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C Reactive Protein (CRP) Level in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</measure>
    <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
    <description>C-reactive protein (CRP) is an inflammation marker produced by the liver. An increase in CRP value may means inflammation in the body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index (BMI) in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</measure>
    <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
    <description>Body Mass Index (BMI) is calculated from subject's weight (kilogram) and height (meter)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Level in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</measure>
    <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
    <description>Insulin is a hormone made by the pancreas that allows the body to use or store sugar (glucose) from the food eaten. Insulin regulates blood sugar level.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LCAT Activity (Lecithin-Cholesterol Acyltransferase) in Control and Chronic Kidney Disease Groups, Mainly to CKD3b, CKD4</measure>
    <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
    <description>LCAT measures phospholipase activity in plasma. Measuring LCAT activity may be useful in clarifying the aspects of lipid metabolism in relation to reverse cholesterol transport
No data collected- no standard deviation calculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CETP Activity (Lecithin-Cholesterol Acyltransferase) in Control and Chronic Kidney Disease Groups, Mainly to CKD3b, CKD4</measure>
    <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
    <description>CETP activity measures the transfers of neutral lipids from high density lipoproteins (HDL) to very low density lipoprotein (VLDL) and low density lipoprotein (LDL). CETP may give us the other clue to lipoprotein metabolism and reverse cholesterol transport pathway
No data collected- no standard deviation calculated</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic renal disease (CKD3b)</arm_group_label>
    <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 30-45</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic renal disease (CKD4)</arm_group_label>
    <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 15-30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chronic renal disease (CKD5)</arm_group_label>
    <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
    <arm_group_label>chronic renal disease (CKD3b)</arm_group_label>
    <arm_group_label>chronic renal disease (CKD4)</arm_group_label>
    <arm_group_label>chronic renal disease (CKD5)</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>Heparin Sodium</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood taken separated into plasma, serum, and red cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a single center cross sectional study of renal failure in comparison to control
        subjects. This is not a treatment or outcome trial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  self report of stable body weight during the past six months;

          -  BMI 18-40 kg/m2; Hemodialysis dependent for at least 3 months, prevalent ESRD (end
             stage renal disease) cohort;

          -  GFR &gt; 15 &lt; 44 ml/min (CKD cohort);

          -  GFR &gt; 60 ml/min (Control cohort).

        Exclusion Criteria:

          -  Diabetes Mellitus (American Diabetes Association definition: fasting glucose &gt;120
             mg/dl);

          -  Evidence of liver disorder, ie; hepatitis

          -  Evidence of thyroid disorders

          -  HIV by medical history (HIV test will not be performed)

          -  Renal transplant recipient

          -  Oral contraceptive/ hormone replacement therapy

          -  Systemic use of systemic or inhaled corticosteroids in the past month

          -  Contraindication to systemic anticoagulation (heparin administration is necessary to
             measure levels of LPL, HL);

          -  Hemoglobin &lt; 8.5 g/dl (anemia);

          -  Current, within 2 months use of any hypolipidemic or anti-diabetic agents;

          -  Patients treated with a fibric acid derivative or niacin in the past 4 weeks;

          -  Urinary protein excretion of greater than 0.5 grams per day;

          -  Any other condition that, in the opinion of the investigators, would put the subject
             at risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George A Kaysen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tjien Dwyer, BS</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353643/</url>
    <description>Nephron Clin Pract. 2012; 122(0): 127-133.</description>
  </link>
  <results_reference>
    <citation>Molfino A, Don BR, Kaysen GA. Comparison of bioimpedance and dual-energy x-ray absorptiometry for measurement of fat mass in hemodialysis patients. Nephron Clin Pract. 2012;122(3-4):127-33. doi: 10.1159/000350817. Epub 2013 May 9.</citation>
    <PMID>23689544</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 10, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <results_first_submitted>May 3, 2018</results_first_submitted>
  <results_first_submitted_qc>April 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2019</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high density lipoprotein (HDL)</keyword>
  <keyword>lipid</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>glomerular filtration rate (GFR)</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>once published; data will be shared</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>once published; data will be shared</ipd_time_frame>
    <ipd_access_criteria>once published; data will be shared</ipd_access_criteria>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.irbnet.org/release/study/overview.do?ctx_id=0&amp;spk_id=855867</doc_url>
      <doc_comment>for a copy of Approved Consent Form-please contact Study Coordinator -Tjien Dwyer at tlthio@ucdavis.edu</doc_comment>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02755818/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02755818/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02755818/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects are recruited from Sacramento areas within 50 miles radius, and University of California, Davis. Subjects of chronic kidney disease (CKD5) are recruited mainly from five DCI (Dialysis Clinic Incorporation) clinics in Sacramento area.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
        <group group_id="P2">
          <title>Chronic Renal Disease (CKD3b)</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 30-45
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
        <group group_id="P3">
          <title>Chronic Renal Disease (CKD4)</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 15-30
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
        <group group_id="P4">
          <title>Chronic Renal Disease (CKD5)</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrawal by PI</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Non-diabetic</population>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
        <group group_id="B2">
          <title>Chronic Renal Disease (CKD3b)</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 30-45
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
        <group group_id="B3">
          <title>Chronic Renal Disease (CKD4)</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 15-30
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
        <group group_id="B4">
          <title>Chronic Renal Disease (CKD5)</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HDL (High Density Lipoprotein) Level in Control and Chronic Kidney Disease (CKD 3b, 4, 5) Groups</title>
        <description>HDL (high-density lipoprotein), is called &quot;good&quot; cholesterol. It binds to cholesterols marked for disposal back to the liver to be digested and disposed by the body. High HDL level may lower your risk for heart disease and stroke.</description>
        <time_frame>HDL (high density lipoprotein) (mg/dL) -- this is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
        <population>Data missing (1) for CKD4 group</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subject has glomerular filtration rate (GFR) of greater than 60 cc/min -- indication of normal kidney</description>
          </group>
          <group group_id="O2">
            <title>Chronic Kidney Disease, Stage 5 (CKD5)</title>
            <description>Subject has glomerular filtration rate (GFR) of less than 15 cc/min - all subjects are on kidney dialysis</description>
          </group>
          <group group_id="O3">
            <title>Chronic Kidney Disease 4 (CKD4)</title>
            <description>Subject has glomerular filtration rate (GFR) of 15-29 cc/min</description>
          </group>
          <group group_id="O4">
            <title>Chronic Kidney Disease Stage 3b (CKD 3b)</title>
            <description>Subject has glomerular filtration rate (GFR) of 30-45 cc/min</description>
          </group>
        </group_list>
        <measure>
          <title>HDL (High Density Lipoprotein) Level in Control and Chronic Kidney Disease (CKD 3b, 4, 5) Groups</title>
          <description>HDL (high-density lipoprotein), is called &quot;good&quot; cholesterol. It binds to cholesterols marked for disposal back to the liver to be digested and disposed by the body. High HDL level may lower your risk for heart disease and stroke.</description>
          <population>Data missing (1) for CKD4 group</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.77" spread="14.88"/>
                    <measurement group_id="O2" value="38.79" spread="11.9"/>
                    <measurement group_id="O3" value="71" spread="NA">only 1 participant - standard deviation not calculated</measurement>
                    <measurement group_id="O4" value="43.50" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LDL Level in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</title>
        <description>LDL (low-density lipoprotein), is a type of cholesterol (fat) circulating in the blood vessels, and can form plaques. High levels of LDL cholesterol may raise your risk for heart disease and stroke.</description>
        <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
        <population>Data missing (1) for CKD4 group</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subject has glomerular filtration rate (GFR) of greater than 60 cc/min -- indication of normal kidney</description>
          </group>
          <group group_id="O2">
            <title>Chronic Kidney Disease, Stage 5 (CKD5)</title>
            <description>Subject has glomerular filtration rate (GFR) of less than 15 cc/min - all subjects are on kidney dialysis</description>
          </group>
          <group group_id="O3">
            <title>Chronic Kidney Disease, Stage 4 (CKD4)</title>
            <description>Subject has glomerular filtration rate (GFR) of 15-29 cc/min – subject has severe kidney disease</description>
          </group>
          <group group_id="O4">
            <title>Chronic Kidney Disease, Stage 3b (CKD3b)</title>
            <description>Subject has glomerular filtration rate (GFR) of 30-44 cc/min – subject has markedly reduced kidney function</description>
          </group>
        </group_list>
        <measure>
          <title>LDL Level in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</title>
          <description>LDL (low-density lipoprotein), is a type of cholesterol (fat) circulating in the blood vessels, and can form plaques. High levels of LDL cholesterol may raise your risk for heart disease and stroke.</description>
          <population>Data missing (1) for CKD4 group</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.93" spread="28.03"/>
                    <measurement group_id="O2" value="75.29" spread="25.17"/>
                    <measurement group_id="O3" value="235" spread="NA">one patient only- no standard deviation calculated</measurement>
                    <measurement group_id="O4" value="112.50" spread="30.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C Reactive Protein (CRP) Level in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</title>
        <description>C-reactive protein (CRP) is an inflammation marker produced by the liver. An increase in CRP value may means inflammation in the body.</description>
        <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
        <population>Data missing (1) for CKD4 group</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subject has glomerular filtration rate (GFR) of greater than 60 cc/min -- indication of normal kidney</description>
          </group>
          <group group_id="O2">
            <title>Chronic Kidney Disease, Stage 5 (CKD5)</title>
            <description>Subject has glomerular filtration rate (GFR) of less than 15 cc/min - all subjects are on kidney dialysis</description>
          </group>
          <group group_id="O3">
            <title>Chronic Kidney Disease, Stage 4 (CKD4)</title>
            <description>Subject has glomerular filtration rate (GFR) of 15-29 cc/min – subject has severe kidney disease</description>
          </group>
          <group group_id="O4">
            <title>Chronic Kidney Disease, Stage 3b (CKD3b)</title>
            <description>Subject has glomerular filtration rate (GFR) of 30-44 cc/min – subject has markedly reduced kidney function</description>
          </group>
        </group_list>
        <measure>
          <title>C Reactive Protein (CRP) Level in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</title>
          <description>C-reactive protein (CRP) is an inflammation marker produced by the liver. An increase in CRP value may means inflammation in the body.</description>
          <population>Data missing (1) for CKD4 group</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.17"/>
                    <measurement group_id="O2" value="0.74" spread="0.64"/>
                    <measurement group_id="O3" value="1.6" spread="NA">one patient only- no standard deviation calculated</measurement>
                    <measurement group_id="O4" value="0.25" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Mass Index (BMI) in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</title>
        <description>Body Mass Index (BMI) is calculated from subject's weight (kilogram) and height (meter)</description>
        <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subject has glomerular filtration rate (GFR) of greater than 60 cc/min -- indication of normal kidney</description>
          </group>
          <group group_id="O2">
            <title>Chronic Kidney Disease, Stage 5 (CKD5)</title>
            <description>Subject has glomerular filtration rate (GFR) of less than 15 cc/min - all subjects are on kidney dialysis</description>
          </group>
          <group group_id="O3">
            <title>Chronic Kidney Disease, Stage 4 (CKD4)</title>
            <description>Subject has glomerular filtration rate (GFR) of 15-29 cc/min – subject has severe kidney disease</description>
          </group>
          <group group_id="O4">
            <title>Chronic Kidney Disease, Stage 3b (CKD3b)</title>
            <description>Subject has glomerular filtration rate (GFR) of 30-44 cc/min – subject has markedly reduced kidney function</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI) in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</title>
          <description>Body Mass Index (BMI) is calculated from subject's weight (kilogram) and height (meter)</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.72" spread="4.42"/>
                    <measurement group_id="O2" value="29.51" spread="5.91"/>
                    <measurement group_id="O3" value="32.87" spread="6.01"/>
                    <measurement group_id="O4" value="26.83" spread="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Level in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</title>
        <description>Insulin is a hormone made by the pancreas that allows the body to use or store sugar (glucose) from the food eaten. Insulin regulates blood sugar level.</description>
        <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
        <population>Data missing (1) for CKD4 and CKD5 group</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subject has glomerular filtration rate (GFR) of greater than 60 cc/min -- indication of normal kidney</description>
          </group>
          <group group_id="O2">
            <title>Chronic Kidney Disease, Stage 5 (CKD5)</title>
            <description>Subject has glomerular filtration rate (GFR) of less than 15 cc/min - all subjects are on kidney dialysis</description>
          </group>
          <group group_id="O3">
            <title>Chronic Kidney Disease, Stage 4 (CKD4)</title>
            <description>Subject has glomerular filtration rate (GFR) of 15-29 cc/min – subject has severe kidney disease</description>
          </group>
          <group group_id="O4">
            <title>Chronic Kidney Disease, Stage 3b (CKD3b)</title>
            <description>Subject has glomerular filtration rate (GFR) of 30-44 cc/min – subject has markedly reduced kidney function</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Level in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups</title>
          <description>Insulin is a hormone made by the pancreas that allows the body to use or store sugar (glucose) from the food eaten. Insulin regulates blood sugar level.</description>
          <population>Data missing (1) for CKD4 and CKD5 group</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.52" spread="5.74"/>
                    <measurement group_id="O2" value="8.02" spread="6.01"/>
                    <measurement group_id="O3" value="8.3" spread="NA">only 1 patient, standard deviation is not calculated</measurement>
                    <measurement group_id="O4" value="4.9" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LCAT Activity (Lecithin-Cholesterol Acyltransferase) in Control and Chronic Kidney Disease Groups, Mainly to CKD3b, CKD4</title>
        <description>LCAT measures phospholipase activity in plasma. Measuring LCAT activity may be useful in clarifying the aspects of lipid metabolism in relation to reverse cholesterol transport
No data collected- no standard deviation calculated</description>
        <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
        <population>Data not generated - due to insufficient number of patient recruited in CKD4 and CKD3b for comparison and analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subject has glomerular filtration rate (GFR) of greater than 60 cc/min -- indication of normal kidney</description>
          </group>
          <group group_id="O2">
            <title>Chronic Kidney Disease, Stage 5 (CKD5)</title>
            <description>Subject has glomerular filtration rate (GFR) of less than 15 cc/min - all subjects are on kidney dialysis</description>
          </group>
          <group group_id="O3">
            <title>Chronic Kidney Disease, Stage 4 (CKD4)</title>
            <description>Subject has glomerular filtration rate (GFR) of 15-29 cc/min – subject has severe kidney disease</description>
          </group>
          <group group_id="O4">
            <title>Chronic Kidney Disease, Stage 3b (CKD3b)</title>
            <description>Subject has glomerular filtration rate (GFR) of 30-44 cc/min – subject has markedly reduced kidney function</description>
          </group>
        </group_list>
        <measure>
          <title>LCAT Activity (Lecithin-Cholesterol Acyltransferase) in Control and Chronic Kidney Disease Groups, Mainly to CKD3b, CKD4</title>
          <description>LCAT measures phospholipase activity in plasma. Measuring LCAT activity may be useful in clarifying the aspects of lipid metabolism in relation to reverse cholesterol transport
No data collected- no standard deviation calculated</description>
          <population>Data not generated - due to insufficient number of patient recruited in CKD4 and CKD3b for comparison and analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CETP Activity (Lecithin-Cholesterol Acyltransferase) in Control and Chronic Kidney Disease Groups, Mainly to CKD3b, CKD4</title>
        <description>CETP activity measures the transfers of neutral lipids from high density lipoproteins (HDL) to very low density lipoprotein (VLDL) and low density lipoprotein (LDL). CETP may give us the other clue to lipoprotein metabolism and reverse cholesterol transport pathway
No data collected- no standard deviation calculated</description>
        <time_frame>This is a cross sectional study; only one measurement collected, termed &quot;baseline&quot;</time_frame>
        <population>Data not generated - due to insufficient number of patient recruited in CKD4 and CKD3b for comparison and analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Subject has glomerular filtration rate (GFR) of greater than 60 cc/min -- indication of normal kidney</description>
          </group>
          <group group_id="O2">
            <title>Chronic Kidney Disease, Stage 5 (CKD5)</title>
            <description>Subject has glomerular filtration rate (GFR) of less than 15 cc/min - all subjects are on kidney dialysis</description>
          </group>
          <group group_id="O3">
            <title>Chronic Kidney Disease, Stage 4 (CKD4)</title>
            <description>Subject has glomerular filtration rate (GFR) of 15-29 cc/min – subject has severe kidney disease</description>
          </group>
          <group group_id="O4">
            <title>Chronic Kidney Disease, Stage 3b (CKD3b)</title>
            <description>Subject has glomerular filtration rate (GFR) of 30-44 cc/min – subject has markedly reduced kidney function</description>
          </group>
        </group_list>
        <measure>
          <title>CETP Activity (Lecithin-Cholesterol Acyltransferase) in Control and Chronic Kidney Disease Groups, Mainly to CKD3b, CKD4</title>
          <description>CETP activity measures the transfers of neutral lipids from high density lipoproteins (HDL) to very low density lipoprotein (VLDL) and low density lipoprotein (LDL). CETP may give us the other clue to lipoprotein metabolism and reverse cholesterol transport pathway
No data collected- no standard deviation calculated</description>
          <population>Data not generated - due to insufficient number of patient recruited in CKD4 and CKD3b for comparison and analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>This is not an interventional study. No adverse event monitored.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
        <group group_id="E2">
          <title>Chronic Renal Disease (CKD3b)</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 30-45
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
        <group group_id="E3">
          <title>Chronic Renal Disease (CKD4)</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 15-30
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
        <group group_id="E4">
          <title>Chronic Renal Disease (CKD5)</title>
          <description>heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis
Heparin: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of study due to low number of enrollment in chronic kidney disease group 3b and 4.
Secondly, chronic kidney disease subjects prefer not to receive heparin. Heparin is necessary for our study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>George Kaysen MD - Principal Investigator</name_or_title>
      <organization>University of California, Davis</organization>
      <phone>916-734-3774</phone>
      <email>gakaysen@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

